Phase I study of chidamide (CS055/HBI-8000), a new histone deacetylase inhibitor, in patients with advanced solid tumors and lymphomas

Phase IIB Multicenter Trial of Vorinostat in Patients With Persistent, Progressive, or Treatment Refractory Cutaneous T-Cell Lymphoma

Elise A. Olsen, Youn H. Kim, Timothy M. Kuzel et al. · Journal of Clinical Oncology · 2007 · 1K citations

Pharmacy, Oncology, Pharmacotherapy +16

Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors

Nagma Khan, Michael Jeffers, Sampath Kumar et al. · Biochemical Journal · 2007 · 710 citations · Full text

Medicine, Oncology, Pharmacology +10

Final Results From a Multicenter, International, Pivotal Study of Romidepsin in Refractory Cutaneous T-Cell Lymphoma

Sean Whittaker, Marie‐France Demierre, Ellen J. Kim et al. · Journal of Clinical Oncology · 2010 · 661 citations

Medicine, Oncology, Pharmacology +13

Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy

Wilko Weichert, A.-E. Roske, Volker Gekeler et al. · British Journal of Cancer · 2008 · 479 citations · Full text

Medicine, Molecular Biology, Oncology +17

Natural Killer Cell–Mediated Lysis of Hepatoma Cells via Specific Induction of NKG2D Ligands by the Histone Deacetylase Inhibitor Sodium Valproate

Sorin Armeanu, Michael Bitzer, Ulrich M. Lauer et al. · Cancer Research · 2005 · 358 citations

Life Sciences, Immunology, Pharmacology +16